January 30, 2013. The FDA considered a new way to approve drugs for use in small patient populations. NRC warn that such a pathway would put patients at risk of harm by giving them poorly studied drugs without knowing if the drugs provide any benefit.
Read More »On Health Policy
Letter to Congressman Markey in Support of VALID Act About Compounding Pharmacies
May 22, 2013. As members of the Patient, Consumer, and Public Health Coalition, we strongly support the Verifying Authority and Legality in Drug (VALID) Compounding Act of 2013. This bill would significantly strengthen FDA oversight of compounding pharmacies and help ensure patients get safe and effective life-saving medical products.
Read More »Comments on Proposed Order Regarding Cranial Electrotherapy Stimulator Devices
May 6, 2013. As members of the Patient, Consumer, and Public Health Coalition, we strongly support the FDA requiring the premarket approval (PMA) process for cranial electrotherapy stimulator devices because they pose substantial risks and the benefits of these devices are “unknown” and there is “limited scientific evidence” regarding their effectiveness.
Read More »Patient, Consumer, and Public Health Coalition Letter Re: HELP Committee’s Draft Proposal on Pharmaceutical Compounding
May 6, 2013. The Patient, Consumer, and Public Health Coalition expressed concern that the draft does not adequately address the public health threats posed by compounding pharmacies and will not do enough to prevent future health care crises. The Coalition provided comments on how to improve the draft to better protect the American public.
Read More »Patient, Consumer, and Public Health Coalition Comments to FDA: Don’t Need a New Pathway for Antibiotics for Limited Populations!
January 30, 2013. The FDA considered a new way to approve drugs for use in small patient populations. NRC warn that such a pathway would put patients at risk of harm by giving them poorly studied drugs without knowing if the drugs provide any benefit.
Read More »